Mirum Pharmaceuticals/$MIRM
13:30
15:10
16:45
18:25
20:00
1D1W1MYTD1Y5YMAX
About Mirum Pharmaceuticals
Mirum Pharmaceuticals Inc. is a biopharmaceutical company focused on developing and commercializing therapies for rare and orphan diseases. Its main product, Livmarli (maralixibat), is an orally administered IBAT inhibitor approved to treat cholestatic pruritus in patients with Alagille syndrome. The company is also developing treatments such as maralixibat for PFIC and ALGS, and volixibat for adult cholestatic liver diseases. Mirum currently has three approved medicines: Livmarli, Cholbam, and Ctexli.
Ticker
$MIRM
Sector
Primary listing
Employees
418
Headquarters
Website
MIRM Metrics
BasicAdvanced
$6.2bn
-
-$15.17
0.52
-
Price and volume
Market cap
$6.2bn
Beta
0.52
52-week high
$114.99
52-week low
$42.89
Average daily volume
1m
Financial strength
Current ratio
2.087
Quick ratio
1.904
Long term debt to equity
132.55
Total debt to equity
133.52
Interest coverage (TTM)
-5.21%
Profitability
EBITDA (TTM)
-50.05
Gross margin (TTM)
81.39%
Net profit margin (TTM)
-140.24%
Operating margin (TTM)
-13.19%
Effective tax rate (TTM)
-0.17%
Revenue per employee (TTM)
$1,360,000
Management effectiveness
Return on assets (TTM)
-5.94%
Return on equity (TTM)
-335.82%
Valuation
Price to revenue (TTM)
9.452
Price to book
25.67
Price to tangible book (TTM)
-533.94
Price to free cash flow (TTM)
-29.493
Free cash flow yield (TTM)
-3.39%
Free cash flow per share (TTM)
-3.465
Growth
Revenue change (TTM)
50.19%
Earnings per share change (TTM)
841.50%
3-year revenue growth (CAGR)
81.18%
3-year earnings per share growth (CAGR)
60.45%
What the Analysts think about MIRM
Analyst ratings (Buy, Hold, Sell) for Mirum Pharmaceuticals stock.
MIRM Financial Performance
Revenues and expenses
MIRM Earnings Performance
Company profitability
MIRM News
AllArticlesVideos
Mirum Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Business Wire·4 days ago
Mirum Pharmaceuticals Prices $600.0 Million Convertible Senior Notes Offering; Refinances a Portion of 2029 Convertible Notes
Business Wire·5 days ago
Mirum Pharmaceuticals to Participate in Upcoming Investor Conferences
Business Wire·6 days ago
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real-time US market data is sourced from the IEX order book provided by Polygon. After-hours US market data is 15 minutes delayed and may differ significantly from the actual tradable price at market open.
Capital at risk
Upcoming events
No upcoming events
FAQs
What’s the current market cap for Mirum Pharmaceuticals stock?
Mirum Pharmaceuticals (MIRM) has a market cap of $6.2B as of May 18, 2026.
What is the P/E ratio for Mirum Pharmaceuticals stock?
The price to earnings (P/E) ratio for Mirum Pharmaceuticals (MIRM) stock is 0 as of May 18, 2026.
Does Mirum Pharmaceuticals stock pay dividends?
No, Mirum Pharmaceuticals (MIRM) stock does not pay dividends to its shareholders as of May 18, 2026.
When is the next Mirum Pharmaceuticals dividend payment date?
Mirum Pharmaceuticals (MIRM) stock does not pay dividends to its shareholders.
What is the beta indicator for Mirum Pharmaceuticals?
Mirum Pharmaceuticals (MIRM) has a beta rating of 0.52. This means that it is less volatile than the market, on average. A beta of 1 would indicate the stock moves in-line with the market, while a beta of 0.5 would mean it moves half as much as the market.